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1. Abstract
The development of multidrug-conjugated polymeric nanoparticles for drug delivery
applications promises more effective forms of cancer therapy based on the target-specific, triggered
release of therapeutic agents at the tumor site. Discrimination between healthy tissue and tumor
cells can be achieved by exploiting the characteristics of the mildly acidic tumor
microenvironment. While previous studies showed the potential of acid-responsive polymeric
nanoparticles, low drug-loading and failure to release drugs in response to tumor-specific pH
conditions remain a challenge in drug delivery and synthetic chemistry.
This work presents the synthesis of acid-degradable star-like polymeric nanogels that allow
high drug-loading and acid-triggered core degradation in tumor tissue based on the brush-first ringopening metathesis polymerization (ROMP) method. These brush-arm star polymer (BASP)
nanogels are composed of two monomers: (1) poly(ethylene glycol) (PEG) norbornene-terminated
macromonomer providing biocompatible and water-soluble features and (2) the acid-cleavable
acetal-based cross-linker enabling acid-triggered core degradation. After brush formation of PEG
macromonomer resulting in the hydrophilic shell, a mixture of PEG macromonomer and crosslinker initiates the formation of the gel-like core via cross-linking.
BASP nanogels were successfully synthesized using various ratios of cross-linker to PEG
macromonomer. Characterization via gel permeation chromatography (GPC) confirmed the
formation of mostly monomodal BASP nanogels with decreasing MW as the amount of PEG
macromonomer is increased. Additional GPC analysis of acid degraded BASP nanogels suggests
that the macromonomer increases the steric hindrance during cross-coupling and core formation
resulting in smaller BASP nanogels. Furthermore, fluorescence studies show the successful loading
of a fluorescein dye into BASP nanogel.
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2. Introduction
2.1. Conventional Cancer Therapy
As the second leading cause of death globally after cardiovascular disease, cancer is
responsible for nearly 1 in 6 deaths according to the World Health Organization.1 The American
Cancer Society estimates that approximately 41 out of 100 men and 38 out of 100 women in the
US will be diagnosed with some form of cancer during their lifetime.2 For decades, the standard
procedure for treating tumor-forming cancer types involved the administration of chemotherapy
with or without initial local forms of therapy such as surgery and radiation therapy.
While the survival rate of most cancer types has gradually improved with the development
of more effective chemotherapeutic agents, severe side effects that typically accompany
chemotherapy remain a major challenge in cancer therapy as they considerably lower the maximum
tolerable dose (MTD). The basic principle of chemotherapy relies on cytotoxic agents that destroy
tumor cells by inhibiting cell proliferation.3 However, as chemotherapeutic agents do not have the
ability to effectively discriminate between healthy cells and tumor cells, they readily accumulate
in rapidly dividing healthy tissue resulting in unfavorable side effects. More effective strategies of
drug delivery have garnered great attention in overcoming the limitations of conventional
chemotherapy.
2.2. Drug Delivery
Conventional free drugs used in chemotherapy most often suffer from unfavorable
pharmacological and physiochemical properties limiting their therapeutic efficacy. Furthermore,
poor solubility of hydrophobic drugs as well as unfavorable pharmacokinetics negatively affect the
blood circulation lifetime presenting a major challenge in the design of therapeutic agents.
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However, in the context of chemotherapy involving highly cytotoxic agents, poor biodistribution
and lack of selectivity of free drugs may pose even greater risk to the patient.
Recent efforts in the field of cancer research have focused on developing methods to reduce
off-target toxicity of anti-cancer drugs by conjugating drug molecules to biocompatible carriers
that provide favorable pharmacological characteristics. Selective accumulation in tumor tissue is
generally achieved via two mechanisms, passive targeting and active targeting, relying on the
affinity of the drug-carrier for tumor cells. At the target site, drugs are selectively released from
the drug-carrier complex and interact with the target cell without affecting peripheral healthy tissue.
2.2.1. Passive Targeting
Passive targeting is based on the transport of the drug-carrier complex through the
bloodstream to the target site. In the absence of specific interactions between nanocarrier and tumor
cell, selective accumulation in tumor tissue is achieved through the enhanced permeability and
retention (EPR) effect. Rapidly growing tumor cell generate new blood vessels via angiogenesis to
meet their increased nutritional needs (Figure 1d).4 Based on the tumor type, these blood vessels
exhibit abnormal leakage with gap sizes between 100 nm to 2 µm, as well as a poor lymphatic
drainage (Figure 1b).5,6 This results in a higher retention ability and accumulation of nanocarriers
in cancerous tissue.7
As no specific targeting moiety is required for passive targeting to occur, the EPR effect is
commonly exploited in the development of nanocarriers for cancer therapy. However, the limited
control of targeting and slow accumulation in tumor tissue requires nanocarriers with particularly
long half-lives in order for the drug to accumulate in significant concentrations.8 Drug delivery
based on passive targeting is further complicated by the high tumor interstitial fluid pressure (IFP)
resulting in decreased uptake and inhomogeneous distribution.9 A study conducted by Matsumura
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et al. suggests that EPR effect may only offer a modest increase in delivery (i.e., less than 2-fold)
compared to normal tissue.10,11 Moreover, only certain tumor types exhibit EPR after they have
reached a sufficient size, significantly limiting the therapeutic use of passive targeting.

Figure 1. Illustration of EPR effect and its impact on nanoparticle delivery. 12 Scheme (A) represents the
microvasculature of normal tissue compared to tumor tissue in (B) where black circles represent nanocarriers. Scanning
electron microscope (SEM) image (C) showing hierarchical microvasculature in normal rat carotid sinus, whereas (D)
depicts the microvasculature in mice lacking an organized arrangement of blood vessels.

2.2.2. Active Targeting
Active targeting has the potential to overcome the limitations of passive targeting providing
a promising method for reducing the off-target toxicity of chemotherapeutic agents. Discrimination
between cancer tissue and healthy tissue relies on the overexpression of specific surface receptor
on tumor cells. In active targeting, nanocarriers are typically conjugated with peripheral binding
epitopes such as antibody fragments or carbohydrates that selectively bind to endocytosis-prone
receptors enabling enhanced cellular internalization. Well-studied attractive targets for active
targeting include the transferrin receptor, the folate receptor, and glycoproteins.13–15 While studies
have shown the increased therapeutic efficiency of drug-loaded nanoparticles employing active
targeting with up to 30-fold increase in delivery relative to normal tissue, the conjugation of
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targeting moieties to nanocarriers still remains a formidable challenge.16–18 As a result of
conjugation, nanocarrier-bound targeting moieties may exhibit decreased receptor affinity
compared to the free circulating equivalent.4
2.2.3. Drug Release Mechanism
While active and passive targeting may prevent the accumulation of cytotoxic agents in
healthy tissue, the mechanism of drug release is just as essential for reducing the side effects of
conventional chemotherapy. In general, drug release is initiated in response to internal and external
stimuli that enable the localized release of therapeutic agents at the target site in a controlled and
sustained manner. Internal stimuli are based on the unique characteristics of tumor tissue enabling
self-controlled drug release without external intervention.
A promising approach for the selective drug release in tumor cells is a pH-triggered release
mechanism exploiting the mildly acidic tumor microenvironment (pH ~ 6.0).19 As tumor cells rely
on increased glycolysis for their rapid proliferation, they produce acidic lactate even under aerobic
conditions according to the Warburg effect ultimately lowering the pH inside the tumor.20 Other
internal approaches focus on the increased reduction potential in the cytosol caused by high
concentrations of glutathione (GSH) enabling the potential use of disulfide linker.21
Drug release triggered by external stimuli provides an external spatial and temporal control
of the release mechanism. Photocleavage in response to UV-irradiation, in particular, offers a wellestablished method for the controlled release of free drug molecules from nanocarriers.
Furthermore, the combination of multiple release mechanisms in a multi-stimuli responsive
nanocarrier may allow for even greater control while preventing premature drug leakage more
effectively.22
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2.2.4. Types of Nanocarrier
The type of nanocarrier utilized in drug delivery is the determining factor in controlling the
pharmacological properties of the drug-carrier complex. Nanoconjugates involving metallic and
polymeric nanoparticles, liposomes, micelles, and antibodies as the carrier (Figure 2) have shown
potential in improving the efficacy of existing chemotherapy while reducing adverse side effects.23
Inorganic nanoparticles offer unique physical and biological characteristics such as high stability,
magnetic, and optical-electronic properties based on their metallic constituents. Furthermore,
controlling the crystal growth enables the synthesis of homogeneous and heterogenous inorganic
nanoparticle typically made out of gold, silver, iron oxide, or copper in various shapes and
sizes.24,25 While certain types of inorganic nanoparticles have gained increasing popularity as highperformance imaging agents, concerns about their biocompatibility and lack of renal clearance
have limited their usage as nanocarriers in cancer research.26,27
Liposomal nanocarriers, however, have received broad attention as the first nanomedicine
in FDA clinical trials followed by the approval of several liposomal formulations for cancer
treatment.28 Liposomes typically consist of a self-assembled phospholipid bilayer encapsulating
the drug preventing undesirable interactions. While liposomal carriers present a well-established
tool in nanotherapeutics due to their straightforward synthesis and facile incorporation of targeting
ligands, their rapid clearance results in unfavorably short circulation half-lives.28 In fact, a recent
study by Petersen et. al. suggests that liposomal formulations do not increase the overall survival
of cancer patients compared to the conventional free drug.29
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Figure 2. Different types of nanocarriers used for drug delivery applications. 30

Closely related to the concept of liposomal transport are polymeric micelles typically
containing amphiphilic block copolymers that self-assemble into spheres with hydrophobic cores
and hydrophilic shells. However, most micelle formulations are still in the early stages of
development with only one non-cancer related FDA-approved micelle to date.28
Promising candidates in overcoming the limitations of other nanocarriers are polymeric
nanoparticles as they tend to be more stable than other nanocarriers.31 Unlike polymeric micelles,
most polymeric nanoparticles possess a dense well-defined polymerized core surrounded by a
polymeric shell. Furthermore, biodegradable polymeric nanoparticles are highly biocompatible and
provide maximum control of the drug release mechanism in response to internal and external
stimuli. Unlike other nanocarriers, polymeric nanoparticles enable the precise ratiometric delivery
of multiple drugs in high concentrations substantially enhancing the efficacy of single-loaded
carriers.32,33 Drug molecules are typically entrapped in the nanoparticle core or conjugated to the
shell effectively preventing premature leakage. A special class of polymeric nanoparticles
represent brush-arm star polymers (BASP) containing a densely cross-linked core and a
Grundler 10

biocompatible shell. A poly(ethylene)glycol (PEG)-based shell, in particular, represents a wellestablished method to enhance the blood circulation lifetime of the nanocarrier by preventing renal
clearance and aggregation.34 In addition to cancer therapy, Hung et. al. have recently shown the
potential of nitroxide-functionalized BASP as metal-free contrast agents that selectively
accumulate in tumor tissue.35
2.3. Brush-Arm Star Polymers
2.3.1. Synthetic Approaches for the Preparation of Star Polymers
Star polymers represent a class of branched polymers with three-dimensional globular
structure typically consisting of linear polymer chains radiating from a central core. Largely driven
by the development of controlled living polymerization techniques, star polymers have gained
increasing popularity in polymer chemistry as materials with predetermined characteristics and a
wide variety of applications.36 The preparation of star polymers is generally divided into three
synthetic approaches: (i) The core-first approach is based on a multifunctional initiator with
multiple initiation sites allowing for the simultaneous polymerization of monomers forming the
arms of the star polymer (Figure 3a). (ii) The grafting to-approach involves the preparation of endfunctionalized polymer arms which selectively couple to a multifunctional linking agent serving as
the core (Figure 3b). (iii) In the arm-first approach, a living macroinitiator or macromonomer (arm)
is prepared followed by the reaction with a difunctional cross-linker initiating cross-linking
reactions between arms radiating from the resulting densely cross-linked core (Figure 3c).
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Figure 3. Schematic illustration of strategies for star polymer synthesis with (a) depicting the core-first approach, (b)
grafting-to, and (c) arm-first.37

Initial attempts to synthesize star polymers were primarily based on the core-first approach
due to the high yields and precise control over the number of arms. However, inherent
disadvantages such as the difficulty in the characterization of polymer arms, the potential of starstar coupling, and the limited number of arms have shifted the focus to grafting to and arm-first
approaches.38,39 Unlike the core-first approach, grafting to and arm-first strategies allow the direct
characterization of polymer arms before core linkage. The grafting to-approach promises the
preparation of star polymers with well-defined macromolecular architecture as it allows the precise
control over the number of arms per linking agent and chain length. However, steric hindrance
around the core typically requires large excess of polymer and long reaction times for adequate
conversion while making it difficult to synthesize star polymers with large number of arms.37
Similar to the graft to-approach, the arm-first strategy enables the preparation of star polymers
containing arms with well-defined degree of polymerization. As this method does not require a
previously formed core with limited number of initiation sites, star polymers with large number of
arms can be produced. Furthermore, the large cross-linked core offers a high capacity for potential
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drug-loading making the arm-first approach an attractive method for designing star polymers for
cancer treatment.39
2.3.2. Polymerization methods
Efforts in synthesizing polymeric nanoparticles rely on highly controllable and efficient
polymerization methods with low polydispersity. Previously applied polymerization methods for
synthesizing polymeric nanoparticles were mainly based on anionic and radical polymerization,
which limits the incorporation of functional moieties (e.g., nitroxides) due to their incompatibility
with radical processes.40,41 Studies by Schrock et. al. have laid the foundation for an alternative
method, the ring-opening metathesis polymerization (ROMP), by reporting the successful
synthesis of star polymers from bis-olefin cross-linkers added to a living polymer chain.42,43
Additional research by Ogawa and Gutekunst has demonstrated the promise of ROMP as a highly
selective method for the one-pot synthesis of star polymers due to its tolerance to most functional
groups in therapeutic agents and low dispersity.44–46 In ROMP involving norbornene monomers, a
transition metal initiator reacts with the double bond of norbornene opening up the cyclohexene
ring in the initiation step (Figure 4). The two most common transition metal initiators utilized in
ROMP are the molybdenum-based Schrock catalyst and the ruthenium-based Grubbs catalysts,
which typically shows greater air stability and tolerance for functional groups.44 As the active
initiator is attached to the monomer, chain growth is achieved through further reaction with
additional norbornene monomers. The propagation step is terminated by the addition of a linear
alkene derivative preventing further chain growth.
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Figure 4. Schematic illustration of initiation, propagation, and termination step in ROMP with generic norbornene
monomer and metal initiator. Addition of a linear monomer (XY) terminates polymerization.

2.3.3. Brush-Arm Star Polymer (BASP)
Professor Jeremiah Johnson et. al. at Massachusetts Institute of Technology have recently
been able to apply ROMP in the context of brush-arm star polymer (BASP).32,47 As illustrated in
Figure 5, BASP contain two functional units: macromonomers (MM) and cross-linkers. The
macromonomer, typically a poly(ethylene glycol) (PEG) derivative, determines the physiological
solubility and cellular uptake of the BASP nanoparticle.34 Functionalities such as drug molecules
can be built into the macromonomer (graft-through approach) enabling the synthesis of
multifunctional BASPs with precise drug ratios. The living brush polymer is formed by ROMP of
PEG-macromonomers upon the addition of an initiator in arm-first polymerization, also referred to
as brush-first polymerization (Figure 5a). Copolymerization with multifunctional norbornene
cross-linkers affords the primary brush initiator with distinct chain length. Subsequent coupling of
two primary brush initiators leads to the formation of brush-arm star polymers with a well-defined
core stabilized by cross-linking between norbornene cross-linkers, as illustrated in Figure 5b. As
the core still contains active initiators and unreacted norbornene groups, further star growth can
occur via the bimolecular coupling of star polymers at longer time scales. Alternatively, the
addition of extra equivalences of MM results in further polymerization (ROMP-out) forming a
Grundler 14

denser shell. Termination of star growth and ROMP-out is achieved through the addition of a linear
monomer or steric interactions.47

Figure 5. Schematic illustration of brush-arm star polymer formation steps: (A) primary brush initiator formation upon
ROMP of PEG-macromonomer and addition of crosslinker, and (B) star formation upon cross-coupling of two brush
polymers. Relative equivalences of PEG-macromonomor and cross-linker are labeled as m and N, respectively.
Adapted from Liu, J.; Burts, A. O.; Li, Y.; Zhukhovitskiy, A. V.; Ottaviani, M. F.; Turro, N. J.; Johnson, J. A. J. Am.
Chem. Soc. 2012, 134 (39), 16339.

The diameter and molecular weight of the resulting BASP can be controlled by varying N,
the degree of polymerization of cross-linker. Furthermore, Liu et. al. demonstrated the effect of
increasing N on the polydispersity, as illustrated in Figure 6a. Multiple mass distributions were
observed for BASP with equal equivalents of cross-linker to MM, whereas increasing the ratio of
cross-linker to MM yielded nanoparticles with low PDI and larger molecular weight. A statistically
significant positive logarithmic relationship was obtained between N and the molecular weight
suggesting increased cross-linking and core size (Figure 6a, b).47 In particular, increasing N by 5
resulted in a doubling of the BASP molecular weight. The opposite trend is observed for varying
m, the degree of polymerization of the macromonomer. At constant N, an increase in m decreases
the molecular weight due to steric hindrance during cross-linking. Thus, resulting BASP will be
smaller in size as further dimerization events are suppressed.
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Figure 6. (A) Differential mass GPC traces for BASPs with N = 10, 15, and 20 after 4 h cross-linking. (B) Refractive
index GPC traces of N = 10–40 BASP where red asterisks indicate unreacted MM and brush polymer. (C) Log 2 plot
of Mw versus N corresponding to BASP series from (B). Reproduced from Liu, J.; Burts, A. O.; Li, Y.; Zhukhovitskiy,
A. V.; Ottaviani, M. F.; Turro, N. J.; Johnson, J. A. J. Am. Chem. Soc. 2012, 134 (39), 16337–16344.

2.3.4. BASP Core Degradation and Drug Release
As the main molecule involved in core formation during BASP synthesis, the choice of
cross-linker provides a powerful tool in modifying the core stability of the particle with respect to
stimuli-responsive core degradation. Cross-linkers used in ROMP-based BASP synthesis typically
consist of a bis-norbornene linked by a variable linker part. Cleavage of this linker in BASP
promises an attractive target for core degradation resulting in regeneration of parent brush polymers
facilitating drug release and efficient in vivo clearance. To date, several different types of crosslinkers that cleave in response to pH, light, and reduction potential have been proposed and
tested.32,48,49 Acid-labile acetal-based cross-linkers, in particular, have shown promising results in
enabling BASP degradation under highly acidic conditions.49 However, rapid core degradation
triggered by slightly acidic pH necessary for selective drug release in tumor tissue remains a
formidable challenge.
As BASP degradation initiated by the cleavage of cross-linker does not affect the linkage
between MM and prodrug, drug release is achieved in a separate mechanistic step enabling specific
individual trigger for core degradation and drug release (Figure 7). A well-established method of
drug release that has recently been applied in the context of PEG-based BASP is the enzymatic
hydrolysis of the MM-prodrug linkage followed by 1,6 elimination.33 These types of linker
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typically consist of amine-containing carbamates or carbonates providing predictable rates of drug
release.50 Other linkers commonly used in research include photocleavable nitrobenzenefunctionalized tether that trigger drug release in response to ultraviolet light.51

Figure 7. Schematic illustration of BASP core degradation followed by drug release. Orange stars represent a generic
drug molecule.

2.3.5. BASP in Cancer Treatment
While research on single-drug-loaded nanoparticles has led to several FDA-approved
nanoparticle-based formulations with improved efficacy of chemotherapy, certain cancer types
may require the combination of multiple drugs for effective treatment.52 Thus, a nanocarrier that
enables the administration of multiple drugs with different biological targets and cytotoxic profiles
promises even more effective forms of cancer therapy. BASPs provide the optimal platform for a
targeted multi-drug delivery with maximum control of drug release kinetics. The graft-through
approach allows the precise tuning and efficient synthesis of nanoparticles with varying drugloading ratios for cancer-specific formulations.
Researchers at Massachusetts Institute of Technology have recently demonstrated the
synthesis of multidrug-conjugated BASP for the ratiometric delivery and synchronized drug release
near their respective MTD.32 BASPs used in their study contained MMs conjugated with
camptothecin and doxorubicin, as well as a cisplatin-based cross-linker representing the first
Grundler 17

successful work on triplex drug delivery according to the authors. Core degradation of BASP was
achieved by reduction of labile Pt-O bonds in the cross-linker resulting in rapid release of cytotoxic
cisplatin. Subsequent drug release of camptothecin and doxorubicin from regenerated brush
polymers occurred via enzymatic hydrolysis and photocleavage, respectively.
Additional studies investigated the therapeutic tolerance and efficacy of this BASP
compared to its analogous free drug formulation in treating certain types of xenograft tumors in
mice.33 RNAi signature assay confirmed that the subcellular mechanism of action of BASP-bound
drugs is equivalent to that of the corresponding free drug resulting in inhibition of cell growth or
apoptosis. Figure 8a demonstrated the passive accumulation of BASP in the tumor via EPR effect
enabled by a blood circulation half-time of 3.2 h. Comparison of the average body mass indicated
consistent body masses for BASP-treated and control mice, whereas mice treated with the free drug
formulation significantly lost body mass before being euthanized after 10 days (Figure 8b). The
efficacy of BASP treatment was evaluated by monitoring the tumor volume progression, as
illustrated in Figure 8c. BASP-treated mice showed a regression in tumor growth compared to the
control group along with an enhanced survival rate (Figure 8c).
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Figure 8. Therapeutic tolerance and efficacy studies of three-drug-conjugated BASP containing cisplatin,
camptothecin, and doxorubicin.33 (a) shows the localization of BASP in two subcutaneous SKOV-3 xenograft tumors
in a NCR-NU mouse observed 20 h after injection via epi-fluorescence with excitation and emission wavelengths of
Cy5.5 fluorophore of 675 nm and 720 nm, respectively. (b) Average body mass and (c) average tumor volume
progression of mice treated with BASP, control, and free drug formulation (blue arrows indicate injections on days 0,
5, 11, and 22). The survival rate of the three groups was assessed via Kaplan-Meier survival curve (d).

While these studies have demonstrated the potential of multidrug-conjugated BASP in
improving the efficacy of conventional chemotherapy, recent efforts focus on further increasing
the drug-loading per particle by structural diversification. Modifying the BASP core with
hydrophilic components to form a star-like nanogel may improve the drug release by enhancing
the diffusion of hydrophobic drugs out of the core as well as leading to a more rapid core
degradation. Furthermore, star-like nanogels have shown to further increase drug-loading levels by
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providing swelling properties.53 In this thesis, we will investigate structural modification methods
to expand the BASP core and increase drug-loading.
2.4. Methodologies
2.4.1. Gel Permeation Chromatography (GPC)
As a type of size-exclusion chromatography, gel permeation chromatography (GPC)
represents the standard methodology for the molecular characterization of branched and
unbranched polymers. First introduced by Moore in 1964, GPC separates a mixture of polymers
based on their hydrodynamic volume.54 Following the general procedure, the analyte mixture is
dissolved in GPC solvent and injected into the instrument. The flow of additional solvent forces
the injected mixture through a column containing microporous gel beads with size-dependent
affinity for analytes, as illustrated in Figure 9. Smaller analytes readily enter the pores and are
retained by the stationary phase, whereas larger analytes are partially excluded by the smaller pore
sizes remaining in the mobile phase. As a result, larger analytes migrate faster through the column
and elute earlier than smaller analytes.
The elution of analytes is continuously monitored by detectors categorized by their
detection method. Concentration-sensitive detectors based on differential refractive index (DRI),
UV/visible absorption, and IR absorption measure the concentration of analyte in the eluent to
calculate molar mass averages and distributions.55 Furthermore, static light scattering detectors
such as low- and multi-angle light scattering (LALS and MALS) provide additional information
about the molar mass and size as well as aggregation effects of the analyte.56 In the context of
BASPs, the shape and width of the analyte peaks obtained by these methods enable the detailed
analysis of polydispersity and BASP composition.
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Figure 9. Schematic illustration depicting the basic principle of gel permeation chromatography.55

2.4.2. Fluorescence Spectroscopy
Fluorescence spectroscopy is a highly sensitive analytical tool for the quantitative
measurement of fluorescence emission from a sample.57 Fluorescence is based on the radiative
transition from an excited electronic singlet state to the ground state in a molecule referred to as
fluorophore. As the fluorescence intensity in dilute samples is proportional to the concentration of
the fluorophore, fluorometry enables the accurate determination of fluorophore concentration in a
sample.58 Fluorophores with distinct excitation and emission wavelengths are typically used to
label non-fluorescent analytes in efforts to relate fluorescence intensity to analyte concentration.
Furthermore, special classes of fluorophores such as fluorescein dye can mimic the affinity of
hydrophobic drug molecules to nanocarriers correlated to the fluorescence intensity of the
nanocarrier-fluorophore complex.
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2.5. Objectives
The overall goal of this work is to improve the architecture of the BASP-platform in efforts
to enhance the drug-loading and core-degradability in response to acidic environment. In particular,
this thesis seeks to accomplish the following objectives:
1. Synthesize acid-labile star-like nanogels containing acetal cross-linker and PEGmacromonomer via brush-first ROMP
2. Investigate the effect of varying the ratio of cross-linker to PEG-macromonomer on core
formation and nanogel size
3. Study the diffusion of a hydrophobic fluorescent molecule in and out the nanogel core
4. Investigate the core degradation of the nanogel in response to acidic pH
Star-like nanogels synthesized by simultaneous addition of cross-linker and PEG-MM during core
formation are hypothesized to have a significantly larger core size and molecular weight compared
to regular BASP. Furthermore, the copolymerization with PEG-MM is expected to decrease the
extent of cross-linking resulting in a more hydrophilic, gel-like BASP core. As a result, the
diffusion of molecules in and out the core as well as feasibility of core degradation in acidic pH
are predicted to improve with the proposed structural changes.
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3. Methods
All reagents and solvents were purchased from commercial suppliers and used as received
unless otherwise noted. Nuclear magnetic resonance (NMR) spectra were recorded on a JEOL
Eclipse 300 MHz NMR spectrometer and a Bruker AVANCE-400 NMR spectrometer. Gel
permeation chromatography (GPC) analyses of BASP were performed at Massachusetts Institute
of Technology (MIT) on an Agilent 1260 Infinity setup with two Shodex KD-806M columns in
tandem and a 0.025 M LiBr DMF mobile phase run at 60 °C. BASP samples for GPC were diluted
in 0.025 M LiBr DMF and filtered through a 0.45 µm PTFE filter. Acid-degraded samples were
prepared by adding a drop of concentrated trifluoroacetic acid (TFA) to the BASP nanogel solution
in dichloromethane. After 24 hours the solvent was removed by vacuum and samples reimmersed
in 0.025 M LiBr DMF before performing GPC measurements. A Wyatt Optilab T-rEX detector
was used to monitor the differential refractive index (dRI) and the light scattering (LS) signal was
acquired with a Wyatt Dawn Heleos-II detector. The fluorescence intensity of BASP samples
containing fluorescein dye were performed on a Photon Technology International QuantaMaster
8000 Fluorimeter.
3.1. Fluorescein Loading of BASP Nanogels
The equivalent volume of 5 mg BASP nanogel sample was added to 2 mL of 1 µM
fluorescein sodium salt in nanopure water. After 24 hours, the solution was dialyzed against 500
mL nanopure water for 1 d using regenerated cellulose dialysis tubing (Spectrum Labs, 8 kDa
MWCO). The solvent was removed by vacuum and the resulting solid reimmersed into 2 mL
nanopure water via sonication for 30s. Samples for fluorescence measurements were prepared by
filling the cuvette with 3 mL of nanopure water followed by the addition of 0.2 mL fluorescein
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loaded sample solution. Fluorescence intensities were obtained using an excitation wavelength of
490 nm with all slits set to 1 nm.
3.2. Fluorescein Dye Release
A cuvette was filled to the top with nanopure water and the cuvette cap with a dialysis
membrane wrapped around (Spectrum Labs, 8 kDa MWCO) placed on top. After a constant
fluorescence reading was obtained at an emission wavelength of 510 nm (excitation wavelength
438 nm, all slits set to 2 nm), 200 µL of fluorescein loaded BASP nanogel sample was added
through a hole to the cuvette cap. Core degradation was initiated 60 min later through the addition
of 23 µL of 1 M trifluoroacetic acid to the cuvette cap lowering the pH of the solution to 2.
3.1. Synthesis of Norbornene-Poly(ethylene glycol) (PEG) Macromonomer

Figure 10. Synthesis of norbornene-poly(ethylene glycol) macromonomer (PEG-MM) from gamma-aminobutyric
acid, cis-5-norbornene-exo-2,3-dicarboxylic anhydride, N-Hydroxysuccinimide, and O-(2-Aminoethyl)poly(ethylene
glycol).47

3.1.1. Norbornene-Butyric Acid 1
A solution of gamma-aminobutyric acid (1.65 g, 16.00 mmol) and cis-5-norbornene-exo2,3-dicarboxylic anhydride (2.50 g, 15.20 mmol) in toluene (75 mL) was stirred at 140 °C in an oil
bath under reflux for 24 h. The resulting product mixture was purified by washing with 1M HCl
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(3x, 75 mL) and brine followed by drying over anhydrous MgSO4 MgSO4. Solvent was removed
in vacuo to afford 1 (2.798 g, 74% yield) as a faint white solid. 1H NMR (300 MHz, CDCl3): δ
6.28 (s, 2H), 3.54 (t, 2H), 3.27 (s, 2H), 2.69 (d, 2H), 2.37 (t, 2H), 1.93 – 1.86 (m, 2H), 1.52 (d, 1H),
1.20 (d, 1H).
3.1.2. Norbornene-N-Hydroxysuccinimidyl (NHS)-Ester 2
N-Hydroxysuccinimide (NHS, 1.94 g, 16.90 mmol), 4- (dimethylamino)pyridine (DMAP,
137 mg, 1.10 mmol) and 1 (2.79 g, 11.20 mmol) were completely dissolved in dichloromethane
(115 mL) before addition of N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride
(EDC, 2.80 g, 16.90 mmol). After stirring the solution at room temperature for 20 h, the resulting
reaction mixture was concentrated by rotary evaporation and purified via silica gel column
chromatography (70% EtOAc/hexanes) to obtain 2 (2.416 g, 41% yield) as a white solid. 1H NMR
(300 MHz, CDCl3): δ 6.29 (s, 2H), 3.59 (t, 2H), 3.28 (s, 2H), 2.83 (s, 4H), 2.71 (d, 2H), 2.65 (t,
2H), 2.05 – 1.98 (m, 2H), 1.53 (d, 1H), 1.19 (d, 1H).
3.1.3. Norbornene-PEG Macromonomer
O-(2-Aminoethyl)poly(ethylene glycol) (1.00 g, 0.33 mmol) and 2 (0.12 g, 0.35 mmol)
were dissolved in 13 mL anhydrous dimethylformamide and stirred at room temperature for 24 h.
Precipitation in diethyl ether (200 mL) followed by vacuum filtration and washing with two
equivalents of diethyl ether yielded PEG-MM (0.930 g, 84% yield) as a white solid. 1H NMR (300
MHz, CDCl3): δ 6.43 (s, 1H), 6.28 (t, 2H), 3.87 (t, 2H), 3.82 – 3.32 (m, 363H), 3.26 (t, 3H), 2.78
(s, 1H), 2.68 (d, 2H), 2.16 (t, 5H), 1.94 – 1.87 (m, 2H), 1.78 (m, 20H), 1.52 (d, 1H), 1.20 (d, 1H).
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3.2. Synthesis of Acetal Cross-Linker

Figure 11. Synthesis of acetal cross-linker (Acetal-XL) from cis-5-norbornene-exo-2,3-dicarboxylic anhydride, 4aminophenol, and 2-chloroethyl vinyl ether.49

3.2.1. Compound A1
A mixture of cis-5-norbornene-exo-2,3-dicarboxylic anhydride (1.175 g, 7.15 mmol), 4aminophenol (1.013 g, 9.28 mmol), and N,N-diisopropylethylamine (1.62 mL, 9.28 mmol) in
toluene (17 mL) was heated at 140 °C for 4 h. After concentration via rotary evaporation, the
solution was re-dissolved in hot methanol (20 mL) followed by filtration. Cooling the filtrate to 0
°C resulted in white crystals which were filtered and recrystallized twice in methanol to afford A1
(1.133 g, 63% yield). 1H NMR (400 MHz, DMSO-d6) δ 9.73 (s, 1H), 7.04-7.00 (m, 2H), 6.84-6.81
(m, 2H), 6.36-6.35 (m, 2H), 3.19-3.18 (m, 2H), 2.80 (s, 2H), 1.47-1.44 (m, 1H), 1.38 (d, 1H).
3.2.2. Compound A2
Pyridinium p-toluenesulfonate (0.061 g, 0.241 mmol) and A1 (0.616 g, 2.41 mmol) were
dissolved in dichloromethane (60 mL) and cooled down to 0ºC in an ice bath followed by dropwise
addition of 2-chloroethyl vinyl ether (1.22 mL, 12.0 mmol). After stirring for 12 h under nitrogen
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atmosphere, the solution was washed with saturated sodium bicarbonate, water, and brine. Drying
over sodium sulfate followed by silica gel chromatography (0%-30% EtOAc/hexanes) yielded A2
(0.804 g, 92% yield). 1H NMR (400 MHz, CDCl3) δ 7.16-7.12 (m, 2H), 7.08-7.04 (m, 2H), 6.30 (t,
2H), 5.45 (q, 1H), 3.92-3.86 (m, 1H), 3.75-3.69 (m, 1H), 3.58-3.54 (m, 2H), 3.35 (s, 2H), 2.79 (s,
2H), 1.57 (d, 1H), 1.42 (d, 1H).
3.2.3. Acetal Cross-Linker
A2, A1, Na2CO3, and 15-crown-5 were dissolved in dimethylformamide (15 mL) and
stirred at 75 °C for 48 h under nitrogen atmosphere. After dilution with ethyl acetate, the reaction
mixture was washed with saturated sodium bicarbonate, water, and brine followed by drying over
sodium sulfate. Purification of the crude product by silica gel chromatography (0%-50%
EtOAc/hexanes) afforded Acetal XL cross-linker (0.241 g, 23% yield). 1H NMR (400 MHz,
CDCl3) δ7.16- 7.08 (m, 6H), 6.92-6.90 (m, 2H), 6.32 (m, 4H), 5.51 (q, 1H), 4.10-4.08 (m, 2H),
4.02- 3.97 (m, 1H), 3.88-3.83 (m, 1H), 3.38-3.37 (m, 4H), 2.81 (d, 4H), 1.59 (dqt, 2H), 1.55 (d,
3H), 1.45 (d, 2H).
3.3. Synthesis of Brush-Arm Star Polymer Nanogels
In a glove box under nitrogen atmosphere, PEG-MM (0.010 g, 0.0031 mmol) was
dissolved in anhydrous 1,4-dioxane (48.0 µL) and freshly prepared Grubbs 3rd generation catalyst
added (0.02 g/mL dioxane, PEG-MM:catalyst = 10) to give a total PEG-MM concentration of 0.05
M. After 20 min stirring at room temperature, a mixture containing the desired equivalents of acetal
XL cross-linker and PEG-MM was prepared from Acetal XL (0.1 M) and PEG-MM (0.05 M)
stock solutions and added to the reaction mixture. The reaction was quenched with ethyl vinyl ether
(20 µL) after additional 100 min of stirring.
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4. Results and Discussion
4.1. Synthesis of BASP Nanogels
BASP nanogels were synthesized via brush-first ROMP involving the homopolymerization
of 10 equivalences of norbornene-functionalized PEG-MM initiated by one equivalence of Grubbs
3rd generation initiator (Figure 12). After the formation of the living bottle-brush polymer a
mixture of PEG-MM and acid-cleavable acetal cross-linker was added to induce core formation
and cross-linking. The ratio of acetal XL (N) to PEG-MM (m) was varied between 10 to 30
equivalences of acetal XL and 0 to 20 equivalences of PEG-MM in order to investigate the effect
on the BASP nanogel structure.

Figure 12. Synthesis of poly(ethylene glycol) BASP nanogel via brush-first ring-opening metathesis polymerization
followed by acid-triggered core degradation.

4.2. Gel Permeation Chromatography Studies
The synthesized BASP nanogels were analyzed for their size and dispersity via GPC. Figure
13 shows the GPC traces obtained for BASP nanogel samples with N = 10 and m = 0, 5, 10, and
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20. The BASP nanogel sample where no PEG-MM was added during cross-linking resulted in a
well-defined peak with the shortest retention time followed by BASP nanogels with m = 20, m =
10, and m = 5. The peaks for BASP nanogels with m = 5 and m = 20 show an almost identical
retention time with the m = 5 sample eluting out slightly earlier. Notably, the m = 5 peak is
significantly broader than m = 0 and m = 20 peaks suggesting multiple mass distributions. The
longest retention time is observed for the m = 10 BASP nanogel corresponding to the lowest MW.
This data indicates that the addition of PEG-MM during cross-linking decreases the MW of the
resulting BASP nanogel.

Figure 13. Refractive index GPC traces of N = 10 BASP nanogels showing the effect of varying the amount of PEGMM added during cross-linking.

A similar trend is observed for BASP nanogels with N = 20 (Figure 14) and N = 30 (Figure
15). In both cases, the m = 0 BASP nanogel exhibits a significantly shorter retention time than
corresponding BASP nanogels with additional PEG-MM added. However, unlike BASP nanogels
with N = 10, the m = 20 BASP nanogel has the longest retention time followed by m = 10 and m
= 5. Generally, the peaks observed in GPC become broader as more PEG-MM is added suggesting
an increasing polydispersity. In particular, the peak for the N = 30, m = 20 BASP nanogel is
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significantly broader than the peaks for BASP nanogels containing less PEG-MM. However, the
well-defined Gaussian peak shape suggests a mostly monomodal MW distribution for all N and m
tested with the exception of m = 0 BASP nanogels.
The shoulder peak observed around 14 min indicates the presence of a second species with
a MW slightly smaller than that of the corresponding cross-linked BASP nanogel. A similar
phenomenon was previously reported by Gao et al. who identified the shoulder peak of a N = 15
BASP with acetal XL as unconverted bottle-brush polymer.49 The shoulder becomes less defined
as m increases indicating increasing conversion of bottle-brush polymer to BASP. Only N = 30
BASPs GPC traces show a shoulder regardless of the equivalences of PEG-MM added.

Figure 14. Refractive index GPC traces of N = 20 BASP nanogels showing the effect of varying the amount of PEGMM added during cross-linking.
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Figure 15. Refractive index GPC traces of N = 30 BASP nanogels showing the effect of varying the amount of PEGMM added during cross-linking.

Direct comparison of GPC traces obtained for regular BASP without the addition of PEGMM during cross-linking is shown in Figure 16a. The N = 10 BASP resulted in the shortest
retention time followed by N = 20 and N = 30 indicating an increasing MW as the equivalence of
acetal XL is increased. These results agree with a previous study by Liu et al. who tested the effect
of varying the ratio of a nitrobenzyloxycarbonyl bis-norbornene cross-linker on the MW of the
resulting BASP.47 The authors found a positive logarithmic relationship between the amount of
cross-linker and the BASP MW based on the increased cross-coupling of bottle-brush polymers.
As previously mentioned, a shoulder around 14 min is observed in the GPC traces of m =
0 BASPs corresponding to unconverted bottle-brush polymer. The shoulder height decreases as N
increases indicating higher conversion of bottle-brush polymer to BASP via cross-coupling. The
increasing efficiency of the cross-coupling step is theorized to be based on the combined effect of
the increasing number of available cross-linking sites as well as the reduced steric hindrance due
to the increased amount of cross-linker and larger core size. This trend is also evident in Figure
16b and c showing the GPC traces of m = 5 and m = 10 BASP nanogels, respectively. However,
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as m is increased to 20, peaks corresponding to N = 10 and N = 20 BASP nanogel almost overlap
indicating a similar MW despite the different amounts of cross-linker added (Figure 16d). Notably,
the peaks for N = 10 and N = 20 BASP maintain their narrow shape suggesting well-defined
monomodal BASP nanogels regardless of m. In contrast, N = 30 BASP nanogel peaks become
significantly broader as m increases correlating to a broader MW distribution.

Figure 16. Refractive index GPC traces of BASP nanogels with (a) m = 0, (b) m = 5, (c) m = 10, and (d) m = 20
showing the effect of varying the amount of cross-linker on the retention time.

These observations raise questions about the structure of the resulting BASP nanogels as
well as their growth mechanism. Unlike hypothesized, the simultaneous addition of
macromonomer and cross-linker during core formation does not increase the MW and size of the
BASP nanogel. The significant shift in retention time between regular m = 0 BASP and m = 5, 10,
20 BASP nanogels suggests that the addition of the macromonomer negatively affects the core
formation step. In fact, the heteropolymerization of macromonomer and cross-linker is expected to
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increase the steric hindrance preventing access to the bottle-brush initiator as shown in the proposed
mechanism in Figure 17. As a result, available cross-linking sites become less accessible as the
macromonomer prevents the interaction with other bottle-brush initiators decreasing the
probability of successful cross-coupling reactions (i.e., formation of BASP nanogel).
While it is unclear how much PEG-MM was incorporated into the BASP core, the obtained
results suggest a saturation level of PEG-MM incorporation based on the ratio of PEG-MM to
cross-linker (m:N). In particular, the Johnson group has found that ROMP of a structurally related
bis-norbornene cross-linker is substantially faster compared to PEG-MM, implying only a limited
incorporation of PEG-MM before cross-coupling occurs.47 This agrees with the observation that
the MW slightly decreases as m increases from 5 to 10 for N = 10 BASP nanogels as indicated by
Figure 13. However, the increase in MW for the m = 20 BASP nanogel suggests an additional
mechanistic step. After cross-coupling and core formation, the BASP nanogel still contains living
initiator that can react with macromonomer that had not been previously incorporated into the
BASP nanogel core in a step referred to as ROMP-out (Figure 17). As a result, the MW and size
of the resulting BASP nanogel becomes larger compared to m = 5 and m = 10 BASP nanogels.
This effect is less evident in N = 20 and N = 30 BASP nanogels as a larger amount of crosslinker allows the incorporation of more PEG-MM in the cross-coupling step as opposed to after the
core is formed (i.e., ROMP-out cannot occur). Furthermore, the increasing broadness of the N =
30 BASP nanogel peak as m increases provides evidence for this theory as the incorporation of
more PEG-MM will ultimately increases the number of statistical combinations during crosscoupling and therefore the polydispersity of the sample (Figure 15).
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Figure 17. Proposed mechanism of BASP nanogel formation via brush-first ring-opening metathesis polymerization
followed by cross-coupling and ROMP-out.

4.3. GPC Acid Degradation Studies
In efforts to analyze the incorporation of PEG-MM into the BASP nanogel, additional GPC
studies were performed with acid-degraded BASP nanogels. This approach allows to determine the
identity of the polymerized bottle-brush polymer chain as well as find evidence on whether ROMPout occurred. Figure 18 shows the GPC traces of acid-degraded N = 10 BASP nanogels with m =
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0, 5, and 10 BASP nanogels shifted to a lower MW confirms successful degradation. In particular,
the m = 0 peak is located at the shoulder of the non-degraded m = 0 BASP nanogel indicating the
regeneration of the parent bottle-brush polymer upon acid degradation.
The continuous shift towards a shorter retention time as m increases implies the
incorporation of additional PEG-MM into the bottle-brush polymer. However, the difference in
retention time between acid-degraded and non-degraded BASP nanogels becomes successively
smaller for m = 5, 10, and 20 BASP nanogels suggesting that corresponding BASP nanogels
contain a smaller number of cross-coupled bottle-brush polymers. In fact, the m = 20 peak overlaps
with that of its non-degraded BASP nanogel implying that no substantial cross-coupling has
occurred. This observation leads to the theory that increasing m increased the steric hindrance of
one bottle-brush polymer cross-coupling with another bottle-brush polymer, which may disprove
the ROMP-out theory as stated in 4.2. Gel Permeation Chromatography Studies.

Figure 18. Refractive index GPC traces of TFA degraded and non-degraded N = 10 BASP nanogels using various
amounts of PEG-MM.

The acid degradation of a BASP nanogel that involved ROMP-out was expected to
regenerate the original bottle-brush polymer (corresponding to ineffective ROMP-out) as well as a
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higher MW brush polymer formed by combination of ROMP-in and ROMP-out, as illustrated in
Figure 19a and b. As a result, a bimodal mass distribution with one peak at a retention time similar
to that of the unreacted bottle-brush polymer and a second peak at a shorter retention would provide
strong evidence for ROMP-out. However, the absence of a shoulder peak corresponding to
ineffective ROMP-out for m = 5, 10, and 20 BASP nanogels suggests the regeneration of a single
high MW species that did not undergo ROMP-out (Figure 19c). In fact, the complete incorporation
of cross-linker and PEG-MM before cross-linking successfully explains the decreasing extent of
cross-coupling observed as the amount of PEG-MM is increased. In contrast, bottle-brush polymer
formed via ROMP-out should result in BASP nanogels with similar levels of cross-coupling (i.e.,
steric hindrance) regardless of the amount of PEG-MM added as cross-coupling occurs before the
incorporation of PEG-MM.

Figure 19. Schematic illustration of species regenerated from acid-triggered BASP nanogel degradation with a)
representing bottle-brush polymer formed by ineffective ROMP-out, b) bottle-brush polymer formed via ROMP-out
and c) bottle-brush polymer formed without ROMP-out.
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The GPC traces obtained for acid-degraded N = 20 (Figure 20) and N = 30 (Figure 21)
BASP nanogels confirm the trend observed for N = 10 BASP nanogels. In particular, the GPC
peaks are continuously shifted towards a shorter retention time as m increases indicating a higher
MW of the regenerated bottle-brush polymer. Notably, the GPC peak for the acid-degraded m =
20 BASP nanogel with N = 20 only overlaps with the right side of the corresponding non-degraded
BASP nanogel peak suggesting that some cross-coupling has occurred to form higher MW species
represented by the left side of the peak. The difference between the acid-degraded and nondegraded GPC peak becomes even larger for the N = 30 BASP nanogel implying increased crosscoupling of bottle-brush polymer. In general, this trend suggests that the extent of cross-coupling
is strictly controlled by the ratio of cross-linker to macromonomer. Cross-linker incorporated into
the bottle-brush polymer provides sites for cross-coupling, whereas the macromonomer introduces
steric hindrance. Thus, adjusting the ratio of cross-linker to macromonomer offers potential in
synthesizing BASP nanogels with precise control over the extent of cross-coupling and crosslinking.

Figure 20. Refractive index GPC traces of TFA degraded and non-degraded N = 20 BASP nanogels using various
amounts of PEG-MM.
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Figure 21. Refractive index GPC traces of TFA degraded and non-degraded N = 30 BASP nanogels using various
amounts of PEG-MM.

4.4. Fluorescence Dye Loading Studies
The diffusion of a molecule in and out the BASP nanogel core was analyzed using
fluorescein dye (Figure 23b) having a comparable size and hydrophobicity compared to common
chemotherapeutic agents such as doxorubicin. BASP nanogels were exposed to a concentrated
fluorescein dye solution. The relative hydrophobicity of the cross-linked core was expected to
trigger the diffusion of dye into the core and effectively load the BASP nanogels. Excess dye not
entrapped in the nanogel core was removed via dialysis against nanopure water before collecting
fluorescence emission measurements. The obtained fluorescence intensities showed a great
variability regardless of the amount of cross-linker and PEG-MM. The substantial decrease in peak
intensity observed for N = 20 BASP nanogels (Figure 22b) compared to N = 10 (Figure 22a) and
N = 30 (Figure 22c) was not reproducible. In fact, the two other sets tested (Figure S1 and S2)
show no particular trend and disagree with the values shown in Figure 22.
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Figure 22. Trial set 1 of fluorescence emission intensities obtained for fluorescein-loaded BASP nanogels with (a) N
= 10, (b) N = 20, and (c) N = 30 using an excitation wavelength of 490 nm.

The variability in the obtained results may be attributed to the sample preparation and
loading procedure. After dialysis, remaining solvent is typically removed to obtain dry dye-loaded
BASP nanogels with known mass. In a subsequent step, the BASP nanogels are reimmersed into
water before determining the fluorescence intensity. However, dried BASP nanogels do not readily
reimmerse back into solution suggesting possible entanglement due to lyophilization. As a result,
the samples were sonicated in an attempt to break up potential entanglement and facilitate
reimmersion. This step may negatively affect the reproducibility as it may trigger the diffusion of
dye out of the nanogel core. Furthermore, it is unclear as to what extent the entanglement is broken
up via sonication. N = 30 BASP nanogels with m = 0, in particular, did not fully go back into
solution even after extensive sonication possibly due to a large hydrophobic cross-linked core.
While dye loading procedure was not reproducible, all BASP nanogels exhibit a higher
fluorescence intensity than the respective fluorescein dye loading solution (Figure 22 dashed line).
As the amount of fluorescein entrapped in the BASP nanogel cannot exceed the starting amount
present in the loading solution, these results suggest a fluorescence enhancing effect caused by the
BASP nanogel.
In order to test this theory, the fluorescence intensity of fluorescein dye solutions was tested
before and after the addition of a small aliquot of BASP nanogel solution resulting in a decrease in
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intensity in contrast to the observed increase for dye-loaded BASP nanogels. This observation
provides strong evidence that the fluorescence enhancement effect can be attributed to the
successful loading of dye into the BASP. In fact, the spatial entrapment of chromophores may
result in Förster resonance energy transfer (FRET). Typically, an excited donor chromophore
transfers energy to an acceptor chromophore via dipole-dipole coupling. However, the rate of
energy transfer decreases as the distance between the donor and acceptor chromophore increases
making FRET a powerful tool to analyze the interactions between molecules.59 While no separate
donor and acceptor chromophores were used in this study, FRET can also occur between similar
chromophores. As shown in Figure 23a, the absorbance and emission spectra of fluorescein exhibit
a spectral overlap between 480 and 530 nm. Thus, the fluorescence emission in this region may
trigger the excitation of other fluorescein molecules nearby via FRET explaining the fluorescence
intensity enhancing effect of dye-loaded BASP nanogels.

Figure 23. (a) Fluorescein absorbance and emission spectrum showing a spectral overlap that can cause FRET.
Reproduced from https://commons.wikimedia.org/wiki/File:Fluorescein_spectra.svg. (b) Chemical structure of
protonated fluorescein molecule.

This effect may potentially enable the direct comparison of loading efficiencies between
different BASP nanogels directly in the dye loading solution. The extent to which FRET occurs
provides valuable information about the amount of fluorescein dye entrapped inside the BASP

Grundler 40

nanogel. Furthermore, the use of a more specific acceptor-donor pair such as rhodamine and
fluorescein would enhance the quality of this study. Conjugation of the acceptor chromophore
rhodamine to the macromonomer allows to monitor the diffusion of fluorescein in and out the
BASP via FRET. Additionally, ICP-MS studies would provide additional information about the
accessibility of the core for small molecules by quantifying how much left-over initiator Ru is
removed from nanogel core through ROMP termination.
4.5. Fluorescence Dye Release Studies
The ability of BASP nanogels to release dye molecules upon acid-triggered core
degradation was attempted using BASP nanogels that had been exposed to a concentrated
fluorescein dye solution. The diffusion of fluorescein dye out of the BASP nanogel was evaluated
by filling a cuvette cap with a dye-loaded BASP nanogel and wrapping a dialysis membrane with
a pore size smaller than that of the BASP nanogel around it similar to the procedure described by
Wuttke et al.60 Fluorescein dye not entrapped in the BASP nanogel will diffuse through the dialysis
membrane into the cuvette allowing the measurement of the fluorescence intensity of the released
dye.
Figure 24a shows the dye release from a N = 20 BASP nanogel with m = 5 using an
emission intensity of 510 nm and an excitation wavelength of 438 nm. After addition of the dyeloaded BASP nanogel to the cuvette cap (Figure 24b inset), the fluorescence intensity immediately
increased in a linear fashion corresponding to the diffusion of dye out of the BASP nanogel even
without core degradation. This observation suggests that the fluorescein dye is rather loosely
associated to the BASP nanogel rather than tightly entrapped inside the core as expected for BASPs
with the dye conjugated to the macromonomer.
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The degradation of the BASP nanogel was triggered by lowering the pH to 2 through the
addition of TFA. As shown in Figure 24a, the addition of TFA resulted in an immediate drop in
fluorescence intensity correlated to the protonation of fluorescein negatively affecting its quantum
yield and emission spectrum.61 As a result, two different standard calibration curves were obtained
for neutral pH as well as pH 2 to correct for this effect and convert fluorescence intensities into
corresponding concentrations. The corrected graph (Figure 24b) shows an increase in fluorescein
dye concentration after the addition of the dye-loaded BASP nanogel. However, the release of
fluorescein dye levels off directly upon addition of TFA.
While it was suspected that degrading the BASP nanogel would result in an immediate
complete release of fluorescein dye, the core degradation may not be fast enough relative to the
time-scale studied in this experiment. Previous studies have shown that the core degradation of
regular BASPs with acetal cross-linker at pH 4 is rather slow taking several days for complete
degradation.49 Assuming a mostly intact BASP nanogel in this study, the decrease in fluorescein
dye release may be correlated to the protonation of the fluorescein as a result of the lower pH.
Protonating fluorescein increases its hydrophobic characteristics enhancing its affinity for the
hydrophobic cross-linked BASP nanogel core.

Figure 24. Dye release study of a fluorescein-loaded N = 20, m = 5 BASP nanogel showing (a) fluorescence intensities
at 510 nm using an excitation wavelength of 438 nm and (b) converted fluorescein concentration over time. Inset:
experimental setup showing dye-loaded BASP in cuvette cap with a dialysis membrane wrapped around. BASP
nanogel solution was added to the cap system after 10 min followed by the addition of TFA after 70 min.
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While this study provides insights into the interactions between fluorescein dye and the
BASP nanogel, comparison between different BASP nanogel architectures would be helpful in
evaluating their affinity for fluorescein dye. A more practically relevant approach to analyze the
dye release ability is based on conjugating the dye or a dye-labelled drug molecule directly to the
macromonomer. Thus, the incorporation of dye into the BASP nanogel can be ensured.
Furthermore, this would allow to mimic the drug release under physiological conditions.
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5. Conclusion
The synthesis of BASP nanogels via simultaneous addition of an acetal cross-linker and
PEG-macromonomer after brush-first ROMP was successfully demonstrated. GPC analysis
indicates the incorporation of PEG-MM into the BASP nanogel core. However, the
heteropolymerization of cross-linker and macromonomer to the bottle-brush polymer increases
steric hindrance during cross-linking resulting in BASP nanogels with lower MW compared to
regular BASP. This effect diminishes as large amounts of PEG-MM (m = 20) is added during the
cross-linking step suggesting the occurrence of an additional mechanistic step after cross-coupling.
This proposed ROMP-out step involves the polymerization of unconverted PEG-MM to the still
active initiator inside the BASP nanogel. This theory is confirmed by GPC acid degradation studies
showing the regeneration of high MW species rather than the parent bottle-brush polymer. These
results show potential for testing the copolymerization with low MW molecules instead of PEGMM that can help control the properties of the BASP nanogel core.
In general, varying the amount of cross-linker suggests a saturation level of PEG-MM that
can be incorporated before cross-coupling occurs related to the ratio of PEG-MM to cross-linker.
However, additional characterization via small angle X-ray scattering would be helpful to analyze
the composition of the BASP nanogel shell and core. Fluorescence studies suggest the successful
diffusion and accumulation of fluorescein dye into the BASP nanogel. Nevertheless, further studies
will be necessary to improve the reproducibility and allow quantitative comparison between
different BASP architectures.
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7. Appendix

Figure S1. Fluorescence emission intensities obtained for fluorescein-loaded BASP nanogels with (a) N = 10, (b) N =
20, and (c) N = 30 using an excitation wavelength of 490 nm.

Figure S2. Fluorescence emission intensities obtained for fluorescein-loaded BASP nanogels with (a) N = 10, (b) N =
20, and (c) N = 30 using an excitation wavelength of 490 nm.
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Figure S3. 1H NMR spectrum of 1 in CDCl3.

Figure S4. 1H NMR spectrum of 2 in CDCl3.
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Figure S5. 1H NMR spectrum of PEG-MM in CDCl3.
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